What the 7-OH Order Says About Gas Station Supplements
Walk into a gas station and look at the shelf behind the register. Between the energy shots and the lighters there is a row of small bottles and foil packs with names that sound like pre-workout drinks. Some of them are caffeine. Others are kratom derivatives concentrated far past anything found in the plant, or tianeptine, an antidepressant that was never approved in this country and that works on the same receptor as an opioid. They sit in the same row at the same counter, and for years the law treated most of them about the same way it treated the caffeine.
That is starting to change, and I think the change is overdue. This summer the DEA began placing concentrated 7-OH products, one family of kratom derivatives, into Schedule I. It is one product on a long shelf. The more interesting story is what the order says about how that shelf finally gets regulated, and how fast everyone downstream has to move when it does.
Nothing on that shelf was approved first
The reason these products reached the checkout counter in the first place is a 1994 law called the Dietary Supplement Health and Education Act. It lets anything marketed as a dietary supplement skip pre-market approval entirely. The FDA does not review a supplement before it goes on sale. It can only act afterward, once a product is already out and the harm is already documented. A drug has to prove it is safe before it reaches people. A supplement has to be proven unsafe after it already has.
For vitamins that bargain has mostly held up. For psychoactive products dressed as supplements it has not. Tianeptine is the clearest case. Emergency physicians have taken to calling it gas station heroin, and an ER doctor writing in Forbes in August 2026 described a query of the FDA's adverse event database that returned 83 tianeptine cases across 2025 and 2026, 79 of them serious, including deaths. The FDA has issued repeated public warnings, sent warning letters to sellers, and named specific products like Neptune's Fix after they were tied to seizures. Eleven states have banned the compound outright. There is still no federal scheduling of tianeptine, so in most of the country it remains on the shelf while the paperwork catches up to the emergency room.
What the 7-OH order actually does
Against that backdrop the 7-OH action is notable for how quickly it moved and how carefully it was aimed. The DEA announced its intent on July 1. The formal notices published in the Federal Register on July 6. Thirty days later the agency was clear to issue the temporary order at any time, and once it publishes it takes effect the same day and runs for two years. From first announcement to earliest possible effect was five weeks.
The aim matters as much as the speed. The order covers products above a small concentration threshold, which means the extracts and pressed tablets sold at many times the potency of the plant, and it names three synthetic cousins so manufacturers cannot sidestep the rule with a molecule tweak. Plain kratom leaf below the threshold is not covered. Whatever the wider kratom debate settles on, that is a surgical cut, aimed at the concentrated products that were engineered to behave like drugs while being sold like snacks.
I will say plainly that I think this is good news, and that it should not stop here. Temporary scheduling is a patch, one compound at a time, two years at a stretch, while the shelf restocks with whatever comes next. A bipartisan bill in Congress would treat the category rather than the compound, which is closer to the right shape for the problem. Until something like it passes, the pattern will stay what it is now, a fast federal order here and a state ban there, while the shelf changes faster than the rules describing it.
The ground now moves in weeks, not years
For the organizations I think about most, the pace is the part that matters. A substance use program's paperwork names substances. House agreements, intake screens, and the handouts clients take home were written on a day when 7-OH was a legal product, and the day the order publishes they are describing a world that no longer exists. The same is true in the eleven states with tianeptine bans, each with its own effective date, and it will be true again for whatever gets scheduled next. Keeping up with that is a job of its own, and the people running these programs already have one. They should be able to focus on their mission rather than watching the Federal Register.
A lot of my work focuses on exactly this seam between rules and day-to-day operations. I know the rules behind the paperwork, including 42 CFR Part 2, and I build on the tools you already use, so a schedule change becomes an afternoon of updates instead of a season of catch-up. If you or anyone you know runs a program that has not had time to fold this summer's changes into their documents, send them to Tinker Works for a free quote!
Sources. DEA announcement, July 1, 2026 (dea.gov). Federal Register, temporary placement of 7-hydroxymitragynine, July 6, 2026. Jesse Pines, Forbes, August 6, 2026. NBC News on Neptune's Fix. Rep. Panetta press release on the reintroduced legislation.